Current Challenges for IDO2 as Target in Cancer Immunotherapy

Current Challenges for IDO2 as Target in Cancer Immunotherapy

Immune checkpoint inhibitors have revolutionized the clinical approach of untreatable tumors and brought a breath of fresh air in cancer immunotherapy. However, the therapeutic effects of these drugs only cover a minority of patients and alternative immunotherapeutic targets are required. Metabolism...

Full description

Bibliographic Details
Main Authors: Giada Mondanelli, Martina Mandarano, Maria Laura Belladonna, Chiara Suvieri, Cristina Pelliccia, Guido Bellezza, Angelo Sidoni, Agostinho Carvalho, Ursula Grohmann, Claudia Volpi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Immunology
Subjects:
IDO2
tryptophan metabolism
pseudoenzymes
NSCLC
PDAC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.679953/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.679953/full

Similar Items